Mitomycin and Ifosfamide (MI) as Salvage Therapy for Metastatic Pancreatic Adenocarcinoma: a Phase II Study.
- To assess the therapeutic activity of a mitomycin C and ifosfamide combination, in
terms of progression-free survival rate at 6 months, in patients with metastatic stage
IV adenocarcinoma of the pancreas.
OUTLINE: Patients receive mitomycin C IV on day 1 and ifosfamide IV on days 1-3. Courses
repeat every 4 weeks for up to 6 courses in the absence of disease progression or
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival at 6 months
every 2 months during therapy; every 3 months thereafter
Michele Reni, MD
Istituto Scientifico H. San Raffaele
Italy: Ministry of Health